Skip to Content

Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC

Download PQI pdf 0.25MB

Last Updated: July 30, 2025

By: Aubrey Lasko, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss the clinical considerations and general management of encorafenib and binimetinib in non-small cell lung cancer.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI